Posted by Michael Wonder on 06 Jan 2020
Innovation in new drug approvals of 2019 advances patient care across a broad range of diseases
6 January 2020 - In 2019, the FDA approved a wide variety of new drug therapies to help patients in need.
The beginning of a new year is always a rewarding time for the many dedicated staff at the FDA's Center for Drug Evaluation and Research (CDER) who work on approving new drug therapies. We look back over the past year and see how the work we did came together to help patients in need — one of the main reasons why many of us, including me, have chosen a career in regulatory science and public health.
In 2019, we approved a wide variety of new drugs never before marketed in the United States, known as "novel" drugs, along with a range of new approvals containing active ingredients already on the market put to new and innovative uses. Many will have a positive, and even life-saving impact, on countless patients' lives.
